Safety and systemic toxicity will be determined by chemical and clinical parameters evaluated at various time points as described in Section 6. Toxicity grading will be evaluated per the CTEP CTCAE v3.0 and monitoring of adverse events will be done per FDA and NCI guidelines. CTCAE v.3.0 criteria was used to evaluate the original data. 6304p Protocol 118 04/06/2016 13 6. PLAN OF TREATMENT The following section outlines the schedule for evalu ation and treatment of patients during the study. A. First Visit -Booster Vaccination #1 1. Sign consent form for the “Supplemental HER2 CTL Peptide -Based Booster Vaccine Study”. 2.